Kartos Therapeutics
Biotechnology company focused on discovery and clinical development of selective oral small-molecule inhibitors targeting the MDM2–p53 interaction for oncology indications. Emphasis on translational research, preclinical mechanism-of-action studies, and execution of Phase I–III multicenter clinical trials, including evaluation of combination regimens and expanded access requests.
Industries
Nr. of Employees
small (1-50)
Kartos Therapeutics
Redwood City, California, United States
Patents
Products
Investigational oral MDM2 inhibitor (oral small-molecule MDM2–p53 inhibitor)
An investigational, selective, orally administered small-molecule inhibitor targeting the MDM2–p53 interaction to restore p53-mediated cell-cycle arrest and apoptosis; evaluated as monotherapy and in combination regimens across hematologic and solid tumor indications.
Navtemadlin
Navtemadlin is a potent and selective investigational cancer therapy designed to inhibit the MDM2 protein, restore p53 function, and promote apoptosis in CD34+ myelofibrosis cells and other advanced cancers with wild-type TP53.
Investigational oral MDM2 inhibitor (oral small-molecule MDM2–p53 inhibitor)
An investigational, selective, orally administered small-molecule inhibitor targeting the MDM2–p53 interaction to restore p53-mediated cell-cycle arrest and apoptosis; evaluated as monotherapy and in combination regimens across hematologic and solid tumor indications.
Navtemadlin
Navtemadlin is a potent and selective investigational cancer therapy designed to inhibit the MDM2 protein, restore p53 function, and promote apoptosis in CD34+ myelofibrosis cells and other advanced cancers with wild-type TP53.
Services
Sponsorship and operational management of multicenter oncology clinical trials from early-phase to randomized Phase 3 studies.
Sponsorship and operational management of multicenter oncology clinical trials from early-phase to randomized Phase 3 studies.
Expertise Areas
- MDM2-targeted oncology drug development
- Translational oncology research
- Clinical trial management (Phase I–III)
- Combination therapy development
Key Technologies
- Small-molecule MDM2 inhibitors
- p53 pathway modulation
- Preclinical cell culture and animal models
- Apoptosis pathway assays (Bcl-2, cytochrome c, caspase activation)
News & Updates
Protocol and study overview for a Phase 3 add-on study evaluating an investigational MDM2 inhibitor plus ruxolitinib versus placebo plus ruxolitinib in myelofibrosis patients.
Poster presentation describing the randomized, double-blind, placebo-controlled Phase 3 POIESIS study details presented at ASH 2024.
Oral presentation covering randomized, multicenter, global Phase 3 BOREAS results comparing an investigational MDM2 inhibitor versus best available therapy in JAK inhibitor relapsed/refractory myelofibrosis.
Poster showing potentiation of apoptosis when adding an MDM2 inhibitor to ruxolitinib in myelofibrosis-derived myeloblasts.
Protocol and study overview for a Phase 3 add-on study evaluating an investigational MDM2 inhibitor plus ruxolitinib versus placebo plus ruxolitinib in myelofibrosis patients.
Poster presentation describing the randomized, double-blind, placebo-controlled Phase 3 POIESIS study details presented at ASH 2024.
Oral presentation covering randomized, multicenter, global Phase 3 BOREAS results comparing an investigational MDM2 inhibitor versus best available therapy in JAK inhibitor relapsed/refractory myelofibrosis.
Poster showing potentiation of apoptosis when adding an MDM2 inhibitor to ruxolitinib in myelofibrosis-derived myeloblasts.